Capricor Therapeutics, Nippon Shinyaku Ink US Pact For Duchenne Muscular Dystrophy CandidateBenzinga • 01/25/22
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.GlobeNewsWire • 01/25/22
Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19GlobeNewsWire • 12/13/21
Here's Why Capricor (CAPR) is Poised for a Turnaround After Losing 19.3% in 4 WeeksZacks Investment Research • 11/19/21
Capricor's CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA DayGlobeNewsWire • 11/12/21
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/10/21
Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/21
Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9GlobeNewsWire • 11/02/21
Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%Benzinga • 09/24/21
Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002GlobeNewsWire • 09/24/21
Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare ConferencesGlobeNewsWire • 09/22/21
Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/07/21
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021GlobeNewsWire • 09/02/21
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21
Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/12/21
Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12GlobeNewsWire • 08/05/21
Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength?Zacks Investment Research • 06/23/21
Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual ConferenceGlobeNewsWire • 06/17/21
Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual MeetingGlobeNewsWire • 05/18/21
Capricor Therapeutics, Inc.'s (CAPR) CEO Linda Marbán on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21